LinkedIn: shaktisingh1

Investigator | Assistant Professor

The Lundquist Institute at Harbor-UCLA Medical Research Center, Torrance, CA, USA

David Geffen School of Medicine, University of California, Los Angeles, CA, USA

Current Research 

• Identification of key virulence factors in fungal pathogens and their interactions with the immune system

• Targeting fungal virulence factors for vaccine and immunotherapeutics development

• Development of a bivalent cross-kingdom vaccine targeting hospital-acquired infections (Candida, Staphylococcus, Acinetobacter, Klebsiella)

Key Expertise

• Host immune cells-pathogen interactions 

• Antigen discovery and immune characterization

• Adaptive immunity against pathogens

• Vaccine and immunotherapeutics development 

• Preclinical and clinical immunogenicity and efficacy evaluation 

Professional Experience

• Research Scientist | Feb 2019- Jun 2022 | The Lundquist Institute at Harbor-UCLA Medical Research Center, Torrance, CA, USA

• Research Fellow | Jan 2017- Jan 2019 | The Lundquist Institute at Harbor-UCLA Medical Research Center, Torrance, CA, USA

• Post-doctoral Research Fellow | Jan 2016- Jan 2017 |  National Cancer Institute (NIH), Frederick, MD, USA

• Graduate Research/ Research Assistant | Sept 2009- Nov 2015 |  Department of Surgery, University of Alberta, Edmonton, Canada

• Junior Research Fellow | Oct 2008- Aug 2009 | Translational Health Science and Technology Institute (THSTI), NII Campus, New Delhi (Now in Faridabad, HR), India

• Research Assistant | June 2006- Sep 2008 | SAS, National Institute of Immunology (NII), New Delhi, India

Education

• Certificate: Molecular Mycology: Current Approaches to Fungal Pathogenesis | July 2019- Aug 2019 | Marine Biological Laboratory, University of Chicago, Woods Hole, MA, USA

• Certificate: Scientists Teaching Science - 9-week Pedagogy course | April 2016- June 2016 | Office of Intramural Training and Education, National Institute of Health (NIH), Bethesda, MA, USA

• Ph.D. (HCV Immunology) | Sep 2009- Nov 2015) | Department of Surgery, University of Alberta, Edmonton, Canada

• M.Sc. Microbiology | Jun 2003- Aug 2005 | Dept. of Microbiology, Chaudhary Charan Singh University, Meerut, India

• B.Sc. Biology, Chemistry |  Jun 1999- Aug 2002 | RK PG College, Chaudhary Charan Singh University, Meerut, India

Research Projects

1. Immunity and molecular pathogenesis of healthcare-associated fungal and bacterial pathogens (2017- current)

• Immunopathogenesis of Candida auris infection and novel vaccine candidate development

• Development and evaluation of dual antigen-based cross-kingdom fungal vaccine targeting healthcare-related infections (Candida albicans, Candida auris, and Staphylococcus aureus, Acinetobacter and Klebsiella)

• Study of mechanism of Rhizopus pathogenesis and virulence markers 

• Therapeutic strategies against fungal infections including anti-toxin/surface antigen-specific monoclonal antibody 

• Evaluation of Candida albicans specific and Staphylococcus aureus cross-reactive T cell immune responses in human subjects from Phase Ib/IIa clinical trial of NDV-3 vaccine

2. Novel HIV vaccine development (2016-2017)

• Development of CMV vector-based DNA immunotherapeutic and prophylactic vaccine for HIV

• Evaluation of different strategies in the macaque model for the induction of qualitative and quantitative humoral and cellular immune responses, and their enhancement using conserved element DNA+ protein co-immunization, immunomodulators such as molecular adjuvants, and recombinant IL-15

3. Immune responses against hepatitis C virus (2009-2015)

• Immunogenicity characterization of HCV antigens in a mouse model using recombinant adenoviral vectors

• Immunosuppressive, immune-dominant, and cross-reactive epitope determination

• Development and evaluation of a dendritic cell-based vaccine for Hepatitis C virus

• Multiple strategies to enhance antigen-specific immune responses, including the use of adjuvants, co-immunization, prime-boost immunization and optimization of dose and route of immunization

• Development of the cell-based assay for antiviral drug testing

4. Development of Vaccine Candidates for Chikungunya Virus (2007-2009)

• Study of growth kinetics of virus in different cell lines, optimizing culture conditions, the scale-up culture of virus stock in tissue culture flasks, roller bottles, cell factories and spinner flasks, and adaptation of seed virus in serum-free media, and purification of chikungunya virus

• Development of attenuated and inactivated chikungunya virus vaccine candidate

• Evaluation of the potency of chikungunya virus vaccine candidates in the mouse model. The LD50 challenge dose of chikungunya virus was determined by injecting a lethal dose of virus.

5. Clinical Trial of Human Rotavirus Vaccine (2006-2009)

• Antibody generation: Purification of double layered virus particles (DLP) from scale-up cultures of rotavirus, generation of hyperimmune sera in rabbits, and purification of immunoassay grade polyclonal anti-rotavirus IgG antibodies

• Assay development: Optimization and validation of various assays for the clinical trial, such as ELISA based detection of rotavirus in clinical samples, viral RNA extraction from clinical specimens, RT-PCR based genotyping assay, IgG and IgA quantitation by sandwich ELISA

• Phase I/II dose escalation, safety, and immunogenicity study of oral attenuated rotavirus vaccine 116E in infants: Processing of clinical specimens, maintaining specimen and data storage, evaluation of clinical specimen for the shedding of vaccine virus strain or the episode of rotavirus infection using antigen ELISA, RT-PCR, and sequencing. It also involved evaluation of seroconversion of IgG and IgA antibodies, clinical data analysis and reporting

• Evaluation of the effect of trans-placental anti-rotavirus IgG on vaccine-induced serum IgA responses in vaccinated children

• Epidemiology of Rotavirus strains circulating in New Delhi Region

6. Japanese Encephalitis Virus (JEV) Molecular Studies (2007-2008)

• Cloning, expression, and purification of JEV envelope protein in E. coli

• Study of interaction between non-coding regions of JEV RNA with human La protein using yeast 2-hybrid system

Professional Activities

Member

• American Society for Microbiology (ASM), 

• Canadian Association for Immunization Research and Evaluation (CAIRE) 

Poster Presentation Judge

• 47th Annual Summer Students’ Research Day, 2014. Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

Editorial Role

• Associate Editor (Guest) for journal "Frontiers Immunology" 

Reviewer

• Frontiers in Immunology (2015-current)

• Frontiers in Microbiology (2018-current)

• Vaccines (2018-current)

• International Journal of Molecular Sciences (2018-current)

• Cells (2019-current)

• Pharmaceutics (2019-current

• Journal of Fungi (2020-current)

• Frontiers in Cellular and Infection Microbiology (2020-current)

• Frontiers in Fungal Biology (2020-current)

Abstract Reviewer

• Canadian Immunization Conference 2018 (Dec 4-6), Ottawa, ON, Canada

Lectures/ Seminars

• Singh S. A vaccine for new emerging multi-drug resistant Candida auris. Sep 26, 2018. ID DIVISIONAL RESEARCH MEETING, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA

• Singh S. Lecture on Introduction to Immunology and Vaccines. CDCRC,  Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA

• Singh S. Recombinant Adenoviral Vector expressing HCV NS4 Induce Protective Immune Responses in a Mouse Model of Vaccinia-HCV Virus Infection: A Dose and Route Conundrum. March 19, 2015; VGTI, Oregon Health & Science University, Portland, OR, USA

• Singh S, et al. Cellular immune responses against NS4, NS5A and NS5B antigens of HCV and their role in viral clearance. Dept. of Surgery Seminars 2010 & 2011, University of Alberta, Edmonton, AB, Canada

• Singh S, et al. Prions (2003), Biochemical Mechanism of Carcinogenesis (2004), Post Transcriptional Modifications in Eukaryotic RNAs (2005). Dept. of Microbiology Seminars 2003- 2005. CCS University, Meerut, UP, India

Conference Presentations

Oral Presentation

• Singh S, et al. The Candida albicans rAls3p-N vaccine (NDV-3A) protects neutropenic mice from multi-drug resistant C. auris infection. 14th ASM Conference on Candida and Candidiasis; 2018 April 15; Providence, Rhode Island, USA

• Singh S, et al. Antiviral immune responses against adenovirus expressing HCV NS4 protein depend upon route and dose of immunization. Immunet Retreat. Jun 21, 2012; Edmonton, AB, Canada

• Singh S, et al. Adenoviral Vector expressing HCV NS4 induces protective immune responses in a Vaccinia-HCV Mouse Challenge Model: A Dose and Route Paradigm. 2013, Tom Williams Surgical Research Day, University of Alberta, Edmonton, AB, Canada

• Singh S, et al. Prions (2003), Biochemical Mechanism of Carcinogenesis (2004), Post Transcriptional Modifications in Eukaryotic RNAs (2005). Dept. of Microbiology Seminars 2003- 2005. CCS University, Meerut, UP, India

Poster Presentation

• Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: A dose and route conundrum. 21st International Symposium on Hepatitis C and Related Viruses. Sep 7-11, 2014; Banff, AB, Canada

• Singh S, et al. Protective immunity against Vaccinia-HCV in a mouse model depends upon route and dose of immunization. CIHR: 27th Canadian Student Health Research Forum (CSHRF) Symposium. Jun 10-12, 2014; Winnipeg, MB, Canada

• Singh S, et al. T cell responses induced by adenoviral vector expressing HCV NS4 antigen are dependent on route of immunization and suppressed by high antigen doses. Immunet Retreat. Jun 10-11, 2011; Lily Lake Resort, Alberta, Canada

Conferences Attended

• GRC: Immunology of Fungal Infections. Galveston, TX, USA, Jan 13-18, 2019

• 14th ASM Candida and Candidiasis Meeting. Providence, RI, USA, April 15-19, 2018

• ID Week: Advancing Science, Improving Care. San Diego, CA, USA on October 4-8, 2017

• 8th Vaccine & ISV Congress, 4th Computational Vaccinology. Philadelphia, PA, USA on Oct 26-28, 2014

• 21st International Symposium on Hepatitis C and Related Viruses (HCV 2014). Banff, AB, Canada on Sept 7-11, 2014 

• CIHR: 27th Canadian Student Health Research Forum (CSHRF) Symposium. University of Manitoba, Winnipeg, MB, Canada on June 9-12, 2014

• ImmuNet (Immunology Network) Retreat 2010, 2011 & 2012. University of Alberta, AB, Canada

• Li Ka Shing Institute of Virology & Gairdner Foundation Symposium 2012. University of Alberta, Edmonton, AB, Canada on May 31 & June 1, 2012

• 5th Indo-Australian Conference on Medical Biotechnology. National Institute of Immunology (NII), New Delhi, India on 11-12 February, 2008

Fellowships | Scholarships | Awards | Grants

Fellowships | Scholarships | Awards

• Lola Ellis Robertson Endowed Scholarship ($ 3080) for the Molecular Mycology: Current Approaches to Fungal Pathogenesis course; Awarded by Marine Biology Laboratory, University of Chicago, Woods Hole, MA, USA.

• American Society for Microbiology (ASM) Travel Award. ASM Candida and Candidiasis Meeting, Providence, RI, USA, April 2018

• Mary Louise Imrie Graduate Student Award. Faculty of Graduate Studies and Research, University of Alberta, Edmonton, AB, Canada. September 2014

• GSA Professional Development Grant. Graduate Student Association, University of Alberta, Edmonton, AB, Canada. September 2014

• CIHR Travel Award (National Competition). Canadian Institutes of Health Research, Canada. June 2014

• Dean’s CIHR Award (CA$18,000/ year), Graduate Fellowship, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, CANADA  Sep 2011- Aug 2015

• Junior Research Fellowship. Translational Health Science and Technology Institute, (DBT India), New Delhi, India. September 2008

• GATE-MHRD Junior Research Fellowship. Organized by Indian Institute of Technology (IITs), funded by Ministry of Human Resource and Development (MHRD), Govt. of India. March 2006

Grants

ONGOING

• NIH National Center for Advancing Translational Science (NCATS) UCLA CTSI Award

Role: Principal Investigator

Project Title: Identification of novel virulence factors on multi-drug resistant Candida auris for vaccine development strategies (mRNA Platform)

• American Heart Association Award

Role: Principal Investigator

Project Title: Identification of novel virulence factors on multi-drug resistant Candida auris for vaccine development strategies (Sub-unit vaccine)

• Clinical and Translational Science Institute (CTSI) 2021 Core Voucher Awards, UCLA, Los Angeles, CA, USA

Role: Investigator

Project Title: Mammalian cells associated expression of multi-drug resistant Candida auris cell wall Proteins 

COMPLETED

• Clinical and Translational Science Institute (CTSI) 2021 Core Voucher Awards, UCLA, Los Angeles, CA, USA

Role: Co-investigator

Project Title: Self-amplifying mRNA-based vaccine targeting Candida infections 

• Clinical and Translational Science Institute (CTSI) 2021 Core Voucher Awards, UCLA, Los Angeles, CA, USA

Role: Co-investigator

Project Title: Development of therapeutic monoclonal antibodies against multi-drug resistant Candida auris

• Clinical and Translational Science Institute (CTSI) 2019 Core Voucher Awards, UCLA, Los Angeles, CA, USA

Role: Co-investigator

Project Title: Evaluation of multi-drug resistant Candida auris Cross-Reactive antibodies and T Cells in humans vaccinated with NDV-3A vaccine.

• Clinical and Translational Science Institute (CTSI) 2018 Core Voucher Awards, UCLA, Los Angeles, CA, USA

Role: Co-investigator

Project Title: Identification of novel surface virulence and adherence factors on multi-drug resistant Candida auris as potential vaccine and immunotherapeutic candidates

Publications | Peer-Reviewed 

2023

1.  Santana DJ, Anku JAE, Zhao G, Zarnowski R, Johnson CJ, Hautau H, Visser ND, Ibrahim AS, Andes D, Nett JE, Singh S*, O'Meara TR. A Candida auris-specific adhesin, Scf1, governs surface association, colonization, and virulence. Science. 2023 Sep 29;381(6665):1461-1467. Epub 2023 Sep 28. PMID: 37769084.

2. Phan QT, Solis NV, Cravener MV, Swidergall M, Lin J, Huang MY, Liu H, Singh S, Ibrahim AS, Mazzone M, Mitchell AP, Filler SG. Candida albicans stimulates formation of a multi-receptor complex that mediates epithelial cell invasion during oropharyngeal infection. PLoS Pathogens. 2023 Aug 23;19(8):e1011579. PMID: 37611070.

3. Singh S, Barbarino A, Youssef EG, Coleman D, Gebremariam T, Ibrahim AS. Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant Candida auris. Journal of Fungi. 2023 Jan 12;9(1):103. PMID: 36675924.

2022

4. Sutar Y, Nabeela S, Singh S, Alqarihi A, Solis N, Filler S, Ghebremariam T, Ibrahim AS, Date A, Uppuluri P.  Niclosamide loaded Eudragit EPO nanoparticles show enhanced Candida biofilm penetration, trigger biofilm detachment and protect from mucosal candidiasis. PLoS Biology. 2022 Aug 17;20(8):e3001762. PMID: 35976859.

5. Singh S, Nabeela S, Barbarino A, Ibrahim AS, Uppuluri P.Antibodies targeting Candida albicans Als3 and Hyr1 antigens protect neonatal mice from candidiasis. Frontiers in Immunology. 2022 Jul 22;13:925821. PMID: 35935947.

6. Phan QT, Solis NV, Lin J, Swidergall M, Singh S, Liu H, Sheppard DC, Ibrahim AS, Mitchell AP, Filler SG. Identification of Serum Bridging Molecules that Mediate Human Endothelial Cell Invasion by Candida species. PLoS Pathogens. 2022 Jul 7;18(7):e1010681. PMID: 35797411.

2021

7. Gebremariam T, Gu Y, Singh S, Kitt TM, Ibrahim AS. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. Journal of Antimicrobial Chemotherapy. 2021 Jul 15. PMID: 34263306. 

8. Ost K, O’ Meara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, Bell R, Catanzaro JR, Song D, Singh S, Call DH, Hwang-Wong E, Hanson KE, Valentine JF, Christensen KA, O’Connell RM, Cormack B, Ibrahim AI, Palm NW, Noble SM & Round JL. Adaptive immunity promotes a mutually beneficial interaction between commensal eukaryotes. Nature. 2021 July 14, 596, pages114–118. PMID: 34262174. 

9. Mamouei Z, Singh S, Lemire B, Gu Y, Alqarihi A, Nabeela S, Li D, Ibrahim AS, Uppuluri P. An evolutionarily diverged mitochondrial protein controls biofilm growth and virulence in Candida albicans. PloS Biology. 2021 March 15. PMID: 33720927.  

10. Soliman SSM*, Baldin C*, Gu Y*, Singh S*, Gebremariam T, Swidergall M, Alqarihi A, Youssef EG, Alkhazraji S, Pikoulas A, Perske C, Venkataramani V, Rich A, Bruno VM, Hotopp JD, Mantis NJ, Edwards JE Jr, Filler SG, Chamilos G, Vitetta ES, Ibrahim AS. Mucoricin is a Ricin-Like Toxin that is Critical for the Pathogenesis of Mucormycosis. Nature Microbiology. 2021 Jan 18. PMID: 33462434. (*Equal contribution) 

2020

11. Iyer KA, Camara K, Daniel-Ivadd M, Trilles R, Pimentel-Elardod SM, Fossen JL, Marchillo K, Liu Z, Singh S, Muñoz JF, Kim SH, Porco JA Jr, Cuomo CA, Williams NS, Ibrahim AS, Edwards JE Jr, Andes DR, Nodwell JR, Brown LE, Whitesell L, Robbins N, Cowen LE. Novel 3,3-diarylated oxindole efflux inhibitor provides a promising approach to combat azole resistance in the emerging fungal pathogen Candida auris. Nature Communications. 2020 Dec 22; 11, 6429. PMID: 33353950. 

12. Singh S, Yanow S and Agrawal B. Editorial: Heterologous Immunity: Implications and Applications in Vaccines and Immunotherapies. Frontiers in Immunology. 2020 July 7; 11:1408. PMID: 32774334. (Editorial) 

13. Youssef EG, Zhang L, Alkhazraji S, Ghebremariam T, Singh S, Yount NY, Yeaman MR, Uppuluri P, Ibrahim AS. Monoclonal IgM antibodies raised against Candida albicans Hyr1 provide cross-kingdom protection against Gram negative bacteria. Frontiers in Immunology. 2020 Feb 18; 11:76. PMID: 32153560. 

2019 

14. Alkhazraji S, Gebremariam T, Alqarihi A, Gu Y, Mamouei Z, Singh S, Wiederhold N, Shaw KJ and Ibrahim AS. Fosmanogepix (APX001) is Effective in the treatment of immunocompromised mice infected with invasive pulmonary Scedosporiosis or disseminated Fusariosis. Antimicrobial Agents and Chemotherapy. 2019 Dec 9; PMID: 31818813. 

15. Gebremariam T, Alkhazraji S, Gu Y, Singh S, Alqarihi A, Shaw KJ, Ibrahim A. Galactomannan is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy. 2019 Nov 4; AAC.01966-19. PMID: 31685475. 

16. Singh S, Uppuluri P, Mamouei Z, Alqarihi A, Elhassan H, French S, Lockhart SR, Chiller T, Edwards Jr JE, Ibrahim AS. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathogens. 2019 Aug 5; 15(8): e1007460. PMID: 31381597. 

17. Alqarihi A*, Singh S*, Edwards Jr JE, Ibrahim AS, Uppuluri P. NDV-3A vaccination protects mice from Candida albicans biofilm infection. Nature Scientific Report. 2019 Apr 17;9(1):6194. PMID: 30996274. (*Equal contribution). 

18. Agrawal B, Gupta N, Vedi S, Singh S, Li W, Garg S, Li J, Kumar R. Heterologous immunity between adenoviruses and hepatitis C virus (HCV): Recombinant adenovirus vaccine vectors containing antigens from unrelated pathogens induce cross-reactive immunity against HCV antigens. Cells. 2019 May 26;8(5): 507. PMID: 31130710. 

2018

19. Mamouei Z, Alqarihi A, Singh S, Shuying Xu, Michael K. Mansour, Ibrahim AS, and Uppuluri P. Alexidine dihydrochloride has broad spectrum activities against diverse fungal pathogens. mSphere. 2018 Oct 31;3(5). PMID: 30381356. 

20. Uppuluri P, Singh S, Alqarihi A, Alqarihi A, Schmidt CS, Hennessey JP, Yeaman MR, Filler SG, Edwards JE, and Ibrahim AS. Human Als3p Antibodies are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. Frontiers in Immunology. 2018 Jun 15; 9:1349. PMID: 29963049. 

21. Singh S, Ramirez E, Doueiri R, Valentin A, Rosati M, Hu X, Keele BF, Shen X, Tomaras GD, Ferrari G, LaBranche C, Montefiori DC, Das J, Alter G, Trinh HV, Hamlin C, Rao M, Dayton F, Bear J, Chowdhury B, Alicea C, Lifson JD, Broderick KE, Sardesai NY, Sivananthan SJ, Fox CB, Reed SG, Venzon DJ, Hirsch VM, Pavlakis GN, Felber BK. DNA and protein co-immunization regimens combined with different Toll-like receptor-4 (TLR-4) based adjuvants induce immune responses controlling SIVsmE660 infection. Journal of Virology. 2018 Jul 17; 92(15). PMID: 29793957. 

2017

22. Agrawal B, Singh S, Gupta N, Li W, Vedi S,  and R. Kumar. Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension. International Journal of Molecular Science. 2017 Jul 27, 18(8):1626. PMID: 28749434. (Review Article)

2016

23. Singh S, Vedi S, Samrat SK, Li W, Kumar R, and Agrawal B. Heterologous Immunity Between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines. PLoS One.  2016 Jan 11; 11(1): e0146404. PMID: 26751211. 

2015

24. Kumar A*, and Singh S*. Editorial: Influenza Virus Vaccines and Immunotherapies. Frontiers in Immunology. 2015 Nov 09; 6:599. PMID: 26635813. (*Equal and Corresponding author, Editorial). 

25. Samrat SK, Vedi S, Li W, Singh S, Samrat SK, Kumar R, and Agrawal B. Immunization with recombinant adenoviral vectors expressing HCV core or F proteins leads to T cells with reduced effector molecules granzyme B and IFN-γ: A potential new strategy for immune evasion in HCV infection. Viral Immunology. 2015 Jul 2; 28(6): 309-24. PMID: 26133045. 

2014

26. Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B. Recombinant Adenoviral Vector expressing HCV NS4 Induce Protective Immune Responses in A Mouse Model of Vaccinia-HCV Virus Infection: A Dose and Route Conundrum. Vaccine. 2014 May 13;32(23):2712-21. PMID: 24631092. 

27. Appaiahgari MB, Glass R, Singh S*, Taneja S, Chandola TR, Bhandari N, Mishra S, and Vrati S. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 2014 Feb 3; 32(6): 651-6. PMID: 24374502. 

28. Samrat SK, Li W, Singh S, Kumar R, and Agrawal B. Alternate reading frame protein (F protein) of hepatitis C virus: Paradoxical effects of activation and apoptosis on human dendritic cells lead to stimulation of T cells. Plos One.  2014 Jan 27; 9(1): e86567. PMID: 24475147. 

2013

29. Chandola TR, Taneja S, Goyal N, Rathore SS, Appaiahgari MB, Mishra A, Singh S*, and Vrati S* and Bhandari N. Descriptive epidemiology of rotavirus infection in a community in North India. Epidemiology and Infection.  2013 Oct; 141(10): 2094-100. PMID: 23298643. 

2009

30. Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, Mishra A, Singh S*, Vrati S*, and Rotavirus Vaccine Development Group. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Disease. 2009 Aug 1; 200(3): 421-9. PMID: 19545211. 

Abstracts  | Peer-reviewed

1. Singh S, Barbarino A, Youssef E, Nabeela S, Gebremariam T, Alkhazraji S, Garry Osteroff, Uppuluri P, Edwards JE, Ibragim AS. Next Generation Als3p/Hyr1p Dual Antigen Vaccine Targeting Multi-Drug Resistant Fungal and Bacterial Infection. GRC Immunology of Fungal Infections; 2023 Jan 22-27; Galveston, TX, USA.

2. Barbarino A, Singh S, Youssef E, Nabeela S, Gebremariam T, Alkhazraji S, Ibrahim AS. Beta-Glucan Chitosan Particle Provides Cross-protection against Multi-drug Resistant Candida auris. GRC Immunology of Fungal Infections; 2023 Jan 22-27; Galveston, TX, USA.

3. McSwiggin H, Magalhaes R, Singh S, Nabeela S, Mattos E, Barbarino A, Yan W, Ibrahim AS, Uppuluri P. A Spatially Resolved Transcriptomic "Atlas" of Oropharyngeal Candidiasis Reveals A Th-2 and Th-17 Response, Similar to Allergic Inflammation. GRC Immunology of Fungal Infections; 2023 Jan 22-27; Galveston, TX, USA.

4. Youseff E, Singh S, Alkhazraji S, Gebremariam T, Ibrahim AS. 1705. Filamentous Hemagglutinin Polyclonal Antibodies Protect against Multidrug resistant Gram-negative bacteria, Open Forum Infectious Diseases, Volume 9, Issue Supplement_2, December 2022, ofac492.1335, https://doi.org/10.1093/ofid/ofac492.1335

5. Singh S, Nabeela S, Barbarino A, Ibrahim AS, Uppuluri P. 574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis, Open Forum Infectious Diseases, Volume 9, Issue Supplement_2, December 2022, ofac492.627, https://doi.org/10.1093/ofid/ofac492.627

6. Singh S, Barbarino A, Youssef E, Nabeela S, Teklegiorgis G, Ibrahim AS. 97. A Cross-kingdom Vaccine Protects against Multiple Healthcare-associated Infections, Open Forum Infectious Diseases, Volume 9, Issue Supplement_2, December 2022, ofac492.175, https://doi.org/10.1093/ofid/ofac492.175

7. Gu Y, Alqarihi A, Singh S, Gebremariam T, Alkhazraji S, Youssef E, Andes D, Ibrahim AS. A Humanized Antibody Targeting the CotH Invasins is Protective Against Murine Mucormycosis, Open Forum Infectious Diseases, Volume 8, Issue Supplement_1, November 2021, Pages S71–S72, https://doi.org/10.1093/ofid/ofab466.119. 

8. Mamouei Z, Singh S, Alquirihi A, Uppuluri P. Evolutionarily acquired insertion sequences in the Candida proteome are required for adaptation and virulence. Candida and Candidiasis; 2021 Mar 21-27; Online, Microbiology Society Soliman SSM*, Baldin C*, Gu Y*, Singh S*, et al. Mucoricin is a Ricin-Like Toxin that is Critical for the Pathogenesis of Mucormycosis. 9th Advances Against Aspergillosis and Mucormycosis (AAAM 2020).  2020, Feb 27-29, 2020 Lugano, Switzerland.  (*Equal contribution)

9. Gebremariam T, Gu Y, Singh S, Kitt T, Ibrahim A. Combination Treatment of Liposomal Amphotericin B and Isavuconazole is Synergistic in Treating Experimental Mucormycosis. Open Forum Infectious Diseases. 2020, Oct. Volume 7, Issue Supplement_1,, Page S420.  [DOI: 10.1093/ofid/ofaa439.935]

10. Agrawal B, Singh S, Gupta N, Vedi S, Li W, Garg S, Li J, Kumar R. Heterologous Immunity and Hepatitis C Virus: Impact on Natural Infection, Pathogenesis and Vaccine Design. Proceedings. 2020, 50, 63.

11. Singh S, Heewon J, Alkhazraji S, Rich A, Ahmed A, Ruback S, Munford R, Vitetta ES, Ibrahim AS. Rhizopus delemar produces a ricin-like toxin that is involved in its pathogenicity. GRC Immunology of Fungal Infections. 2019 Jan 13-18; Galveston, TX. 

12. Singh S, Uppuluri P, Alqarihi A, Elhassan H, French S, Lockhart SR, Chiller T, Edwards JE and Ibrahim AS. Candida auris possesses homologs of Candida albicans Als3, and can be targeted by the vaccine NDV-3A. GRC Immunology of Fungal Infections. 2019 Jan 13-18; Galveston, TX.

13. Mamouei Z, Singh S, Alqarihi A, Zeng G, Wang Y, Edwards JE, Ibrahim AS, Uppuluri P. A Mitochondrial Complex 1 protein encoded by orf19.2500 is critical for Candida albicans growth on alternative carbon sources, immune evasion and virulence. GRC Immunology of Fungal Infections. 2019 Jan 13-18; Galveston, TX.

14. Singh S, Uppuluri P, Alqarihi A, Hennessey JP, Edwards JE, Ibrahim AS. The Candida albicans rAls3p-N vaccine (NDV-3A) protects neutropenic mice from multi-drug resistant C. auris infection. 14th ASM Conference on Candida and Candidiasis. 2018 April 15; Providence, Rhode Island, USA.

15. Alqarihi A, Singh S, Edwards JE, Hennessy JP, Ibrahim AS, Uppuluri P. Murine antibodies induced by an NDV-3A vaccine containing rAls3p-N, abrogate Candida albicans biofilm formation. 14th ASM Conference on Candida and Candidiasis. 2018 April 15; Providence, Rhode Island, USA.

16. Mamouei Z, Singh S, Alqarihi A, Zeng G, Wang Y, Edwards JE, Ibrahim AS, Uppuluri P. Dispersal cells from glucose-replete C. albicans biofilms express a pre-adaptive response of carbon starvation: role of a novel gene orf19.2500. 14th ASM Conference on Candida and Candidiasis. 2018 April 15; Providence, Rhode Island, USA.

17. Felber, Barbara, Shakti Singh, Antonio Valentin, Margherita Rosati, Eric Ramierz, Rami Doueiri, Xintao Hu, et al. DNA and protein co-delivery vaccines using TLR-4-based adjuvants induce potent immune responses able to delay heterologous SIV acquisition. Journal of Medical Primatology. 2018, 47:313–313. WILEY.

18. Felber B, Singh S, Valentin A, Rosati M, Ramierz E, Doueiri R, Hu X, Bear J, Hirsch V, Broderick K, Sardesai N, Reed S, Trinh H, Rao M, Montefiori D, Ferrari G, Shen X, Tomaras G, Pavlakis G. DNA and protein co‐delivery vaccines using TLR‐ 4‐based adjuvants induce potent immune responses able to delay heterologous SIV acquisition. 35th Annual Symposium on Nonhuman Primate Models for AIDS. 2017, Aug 22-25; Madison, Wisconsin, USA.

19. Pavlakis G, Bergamaschi C, Ng SSM, Valentin A, Watson D, Nagy B, Hu X, Alicea C, Jensen S, Fox B, Moysi E, Petrovas C, Singh S, Bear J, and Felber B. Development of heterodimeric IL-15 for cancer immunotherapy. International Conference on Human & Translational Immunology. Sep 16-21, 2017; Rhodes, Greece.

20. Singh S, Li W, Kumar R, Agrawal B. Fine-tuning of host immune responses: A tale of adeno-vector expressing hepatitis C virus antigen NS4. 8th Vaccine & ISV Congress. Oct 26-28, 2014;  Philadelphia, PA, USA.

21. Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B. Fine-tuning of host immune responses: A tale of adeno-vector expressing hepatitis C virus antigen NS4. 3rd International Conference and Exhibition on Clinical & Cellular Immunology. Sep 29 - Oct 01, 2014; Baltimore, USA.

22. Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: A dose and route conundrum. 21st International Symposium on Hepatitis C and Related Viruses. Sep 7-11, 2014; Banff, AB, Canada.

23. Singh S, Li W, Kumar R, Agrawal B. Protective immunity against Vaccinia-HCV in a mouse model depends upon route and dose of immunization. 27th CIHR-CSHRF (CIHR-Canadian Student Health Research Forum) Symposium. June 10-12, 2014; Winnipeg, MB,Canada.

24. Singh S, Li W, Tyrrell LJ, Kumar R, Agrawal B. Antiviral immune responses against adenovirus expressing HCV NS4 protein depend upon route and dose of immunization. Immunet Retreat. June 21, 2012; Edmonton, Alberta, Canada.

25. Singh S, Li W, Kumar R, Tyrrell LJ, Agrawal B. CD4+ T cell responses induced by adenoviral vector expressing HCV NS4 antigen are dependent on route of immunization and suppressed by high antigen doses. Immunet Retreat. June 10-11, 2011; Edmonton, Alberta, Canada.

Patents

1. Singh S, Edwards J, Uppuluri P, Ibrahim AS. Methods of Treatment for Candida auris Infections. PCT/US2018/026889, EP18166876.5; Publication Date: Oct 16, 2019. [Link]

2. Singh S, Kumar R. & Agrawal B. Methods of Inducing Immune Response to Hepatitis C Virus. US patent application No. 62/103919; PCT Application No. CA2016/000015; Publication No. WO/2016/112459, Publication Date: July 21, 2016. [Link]

Thesis | Edited Books | Book Chapters

Doctoral Thesis

• Singh, S. Immune Responses against Hepatitis C Virus. PhD Thesis, Education and Research Archive. 2015, September 24, University of Alberta, Edmonton, AB, Canada. [DOI:10.7939/R35T3G74P].

Books Edited 

• Kumar A, Singh S, eds. (2016).  Influenza Virus Vaccines and Immunotherapies. Lausanne: Frontiers Media SA.  ISSN 1664-8714. ISBN 978-2-88919-811-5. [DOI: 10.3389/978-2-88919-811-5].

• Agrawal B, Yanow S, Singh S, eds. (2020). Heterologous Immunity: Implications and Applications in Vaccines and Immunotherapies. Lausanne: Frontiers Media SA. ISSN 1664-8714. ISBN 978-2-88963-965-6. [DOI: 10.3389/978-2-88963-965-6].

Book Chapters

1. Lionakis MS, Singh S, Ibrahim AS, Edwards JE (2022). Chapter: 216. Candidiasis. In Dennis L. Kasper and Anthony S. Fauci (eds.) Harrison's Principal’s of Internal Medicine. McGraw Hill Publishers, 21st Edition, ISBN: 978-1-264-26846-7.

2. Singh S, Ibrahim AS, Edwards JE (2019).  Candida auris: An emerging multi-drug resistant Candida species.  In J. Larry Jameson, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, Dan L. Longo, Joseph Loscalzo (eds.) Harrison's Principles of Internal Medicine, 20th Edition. McGraw Hill Publishers.

3. Singh S, Kumar R, and Agrawal B (2018). Future of Adenoviruses as Vaccine Vector. In Yulia A Desheva (eds.) Adenoviruses, London, United Kingdom: Intech Publishers. [DOI: 10.5772/intechopen.79697].

4. Sarkar A, Kundu S, Singh S, and Sen S (2018). Data Mining in Nutrigenomics. In Shampa Sen, Leonid Datta and Sayak Mitra, eds. Machine Learning and IoT: A Biological Perspective. (pp 40-53). New York, USA: CRC Press, Taylor & Francis Group. ISBN 9781138492691.